SS
Uploaded bySabarinath Suryaprakash
PPTX, PDF2,321 views

SUN PHARMA & PHARMA INDUSTRY 2015

Ervas Pharmaceuticals' mission is to make herbal wellness accessible to everyone and promote the belief that good health should be available to all. The company produces herbal medicines with the goal of improving health and wellness. Ervas focuses on natural and herbal remedies to help more people attain better health.

Embed presentation

Downloaded 31 times
ERVAS PHARMACEUTICALS HAVE NATURAL LIVE NATURAL MISSION: ERVAS’ MISSION IS TO MAKE HERBAL -WELLNESS A PART OF EVERY HOME AND TO CREATE BELIEF THAT GOOD HEALTH SHOULD BE ACCESSIBLE TO EVERYONE
GROUP MEMBERS PRAVEEN KUMAR AZHARDEEN SABARINATH D.S SYED MOHAMMED MOHAMED ABUBACKER vIGNESHWARAN
PHARMACEUTICAL INDUSTRY
PHARMACEUTICAL INDUSTRY  The Indian Pharmaceutical Industry currently tops the chart amongst India’s Science based Industries with wide ranging capabilities in the complex field of drug manufacture and technology.  A highly organized sector, the Indian Pharmaceutical Industry is expected to expand at a CAGR of 23.9% by 2020.  It ranks very high among all the third world countries, in terms of technology, quality and the vast range of medicines that are manufactured
DEVELPOMENT OF PHARMACEUTICAL INDUSTRY IN INDIA  INDIAN PHARMACEUTICAL MARKET HAS REACHED 10TH PLACE IN THE WORLD MARKET
INCREMENTAL GROWTH OF INDIA-2015 INDIAN PHARMACEUTICAL INDUSTRY HAS REACHED TOP 3RD IN INCREMENTAL GROWTH OF THE SECTOR AS COMPARED TO US(1ST PLACE) AND CHINA(2ND PLACE)
CAGR REPORT-2015 ON INDIAN PHARMA MARKET  INDIAN PHARMA MARKET IS LIKELY TO TRIPLICATE BY 2015
 Between 2012-2018, the “patent cliff" will wipe an estimated $148 billion off pharmaceuticals industry revenues due to many drugs coming out of patents  Rising cost of R&D, the cost of bringing a molecule to market globally is estimated to be from $800 million to $4 billion.  On average, out of every 10,000 molecules been developed; only one or two are likely to reach the market.  Increasing government pressure, with harsher price controls and taxes.  European Medical Agency (EMA) and the US Food and Drug Administration (USFDA) are focusing on risk management; thereby putting pressures on profitability of pharmaceutical companies. Issues for the Industry
SWOT Analysis Of Indian Pharmaceutical Industry Strengths Weaknesses Opportunities Threats •Low cost of skilled manpower •Access to large pool of highly trained scientists •Strong marketing and distribution network •Proven track record in design of high technology manufacturing devices •Low cost of innovation, manufacturing and operations •Stringent pricing regulations •Poor transport and medical infrastructure •Lack of data protection •Very competitive environment •Poor health insurance coverage •Production of low quality drugs tarnishes image of industry abroad •Low investment in innovative R&D •Increase in per capita income •Global demand for generics rising •Increasing population with more sedentary lifestyle •Increasing health insurance sector •Significant investment from MNCs •Medical tourism •Cheap, diverse clinical trials •Global outsourcing hub due to low cost of skilled labor •Other low cost countries affecting demand •Government regulations changing •Expanding of Drugs Price Control Order •Lack of investment in infrastructure •Wage inflation •R&D restricted by lack of animal testing and outdated patient office •Counterfeiting threat
GENERIC INDUSTRY THE FOLLOWING ARE SOME OF THE GENERIC DRUG MANUFACTURERS  Actavis  Acura pharmaceuticals  Apotex  Aspen Pharmacare  Bio pharma  EMS  Galex  Getz pharma  Hikma Pharmaceuticals  Hospira  Incepta Phamraceuticals  Medinfar  North China pharmaceuticals group corp  Perrigo  Ranbaxy Laboratories  Saidal  Simcere Pharmaceuticals  Stada Arzneimittrl  Sun Pharmaceuticals  Synthon  Teva Pharmaceuticals  Torque Pharmaceuticals
NON GENERIC INDUSTRY THE FOLLOWING ARE SOME OF THE NON GENERIC INDUSRTRY IN PHARMACEUTICAL SECTOR  GLENMARK  ABOTT INDIA  BIOCON  ALEMBIC PHARMA  SANOFI INDIA  WOCKHARDT  PFIZER  NECTAR LIFE  AJANTA PHARMA  SHARON BIO MEDI  GRANULES INDIA  UNICHEM LABS  AARTI DRUGS
132 4.1 0 2 4 6 8 10 12 14 16 18 20 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 US France UK Australia Japan Brazil Russia South Africa China India Indonesia kenya Ghana % GDP Per Capita US $ Per Capita Spent on Healthcare % GDP Spent on Healthcare Investment Comparison
MODE OF ENTRIES OF FOREIGN PHARMAS TO INDIA THE FOLLOWING ARE SOME OF THE FOREIGN MULTINATIONAL PHARMACEUTICAL COMPANIES WHICH CAME TO INDIA THROUGH OUR INDIAN PHARMA COMPANIES . THEY ARE LISTED BELOW. MULTINATIONAL PHARMA - INDIAN PHARMA MERCK & CO - SUN PHARMACEUTICALS PFIZER - AUROBINDO PHARMA, CLARIS LIFESCIENCES STRIDES ARCOLABS GLAXOSMITHKLINE - DR.REDDY’S LABORATORIES ASTRAZENECA - TORRENT PHARMACEUTICALS , INTAS PHARMACEUTICALS , AUROBINDO PHARMA DAICHII SANKYO - RANBAXY ABOTT - PIRAMAL HEALTHCARE SANOFI AVENTIS - SHANTHA BIOTECH MYLAN - MATRIX RECKITT BENCKISER - PARAS HOSPIRA - ORCHID FRESENIUS KABI - DABUR PHARMA
MAJOR MEMBERS OF INDIAN PHARMA INDUSTRY The following are the major pharma companies in India . They are  CIPLA  DR.REDDY’S LABS  LUPIN  CADILA HEALTH  TORRENT PHARMA  GLAXOSMITHKLINE  JUBILANT LIFE  IPCA LABS  DIVIS LABS  SUN PHARMA  PIRAMAL ENTER  GLENMARK  ABOTT INDIA  BIOCON  ALEMBIC PHARMA  SANOFI INDIA  WOCKHARDT  PFIZER  NECTAR LIFE  AJANTA PHARMA  SHARON BIO MEDI  GRANULES INDIA  UNICHEM LABS  AARTI DRUGS
OUR COMPANY OUR PROJECT IS ABOUT THE INDIAN PHARMACEUTICAL GIANT , SUN PHARMACEUTICALS WHY SUN PHARMACEUTICALS ? ACTUALLY IT IS A MILLION DOLLAR QUESTION WHY WE TOOK SUN PHARMA THAN SOME OTHER COMPANY? SUN PHARMACEUTICALS IS NOW THE TOP PHARMACUTICAL COMPANY IN INDIA. BUT IN 1983, WHEN MR.DILIP SHANGHVI WHO WAS THE SON OF A DRUG WHOLESALE DEALER , HE SUDDENLY THOUGHT THAT WHY INSTEAD OF DEALING WITH DRUGS , WHY DON’T WE PRODUCE IT?? THIS HAS MADE HIM TO START A PHARMACEUTICAL COMPANY WITH A VERY VERY SMALL CAPITAL OF JUST ₹ 10000 . BUT NOW IT HAS AN ASSET VALUE OF RS.9816 CRORES WITHIN A DECADE. AND MOREOVER , HE HAD MADE THE WHOLE WORLD TO TURN AROUND US AND MADE THEM FEEL THAT THERE IS AN INDIAN PHARMACEUTICAL COMPANY THAT CAN COMPETE THE WORLD MARKET. NOW , SUN PHARMACEUTICALS IS THE TOP 1ST PHARMACEUTICAL COMPANY IN INDIA AND TOP 5TH IN WORLD GENERIC PHARMACEUTICAL MARKET. THIS IS THE MAIN REASON WHY WE TOOK SUN PHARMACEUTICALS
SUN PHARMACEUTICALS (P) LTD TAG LINE LEADERSHIP THROUGH FOCUSED RESEARCH MISSION MISSION OF GIVING AN IMPETUS TO RESEARCH & DEVELOPMENT IN INDIA VISION TO DEVELOP MEDICAL RESEARCH IN UPCOMING FUTURE
SUN PHARMACEUTICALS  SUN PHARMACEUTICALS LTD is a multinational Pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and Active Pharmaceutical Ingredients (API) primarily in India and in United States.  The company offers formulations in various therapeutic areas such as cardiology, psychiatry, neurology, gastroenterology and diabology.  It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anticancer, steroids peptides, sex hormones and controlled substances  Pharmaceutical Giant SUN PHARMACEUTICALS LIMITED (NET PROFIT OF ₹ 2,828 CRORE IN FY14-15) has topped as No.1 Pharmaceutical Industry in India in 2015 against its best rivals CIPLA LABORATORIES (NET PROFIT OF ₹ 1,181 CRORE), LUPIN LABS (NET PROFIT OF ₹ 2,397 CRORES) DR.REDDY’S LABORATORIES (NET PROFIT OF ₹ 1,679 CRORES) AND ETC..
HISTORY OF THE COMPANY  Established by MR.DILIP SHANGHVI in 1983 in VAPI with five products to treat psychiatry ailments.  Cardiology products were introduced in 1987 followed by Gastroenterology products in 1989.  Today it is the largest chronic prescription company in India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology, and gastroenterology and nephrology  At present, SUN PHARMA has a net income of ₹2,828 crores and with Total Asset value of ₹9816 crores and the current market price of a share is ₹927.25 per share (as on 19/08/2015)
BOARD OF DIRECTORS ISRAEL MAKOV DILIP SHANGHVI SUDHIR V. VALIA SAILESH T. DESAI HASMUKH S SHAH KEKI M MISTRY ASHWIN DANI MOHANCHAND
ACQUISITION & JOINT VENTURES  KNOLL PHARMACEUTICALS & MJ PHARMA – 1996  TAMIL NADU DADHA PHARMACEUTICALS LTD -1997  CARACO PHARMACEUTICALS – 1997  NATCO PHARMA – 1998  MILMET LABS & GUJARAT LYKA ORGANICS – 1999  PRADEEP DRUG COMPANY – 2000  PHLOX PHARMA – 2004  ABLE LABS – 2005  CHATTEM CHEMICALS – 2008  TARO PHARMACEUTICALS – 2010  MSD – 2011  DUSA PHARMACEUTICALS – 2012  INTREXON – 2013  RANBAXY LABORATORIES - 2014
GLOBAL PRESENCE  With global revenues of over US$ 4.5 billion, SUN PHARMA is the fifth largest specialty generic pharmaceutical company in the world. They provide high quality affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide. Sun pharma also includes the largest and most trusted pharmaceutical company. Their global presence is supported by 45 manufacturing facilities across 5 continents.  In the US market contributes a significant share of or revenues, they are the leader in the generic dermatology segment,. They have strong capabilities in developing generic and complex products with a robust pipeline of 149 ANDAs including high value first-2-file (FTF) opportunities. They have an established presence in Europe and key high growth emerging markets like Russia , Romania , south Africa , brazil and , Malaysia.
LOCATIONS  HEADQUARTERS – GUJARAT  CORPORATE OFF – MUMBAI  FACTORY PLANTS - Dadra &Nagar havelli Gujarat Maharashtra Kanchipuram Andheri Jammu & Kashmir Ohio – US New jersey – US Michigan –US Bangladesh Hungary Sikkim Mexico
PRODUCTS PRODUCED They produce drugs for the following categories of treatments. They are  Psychiatry  anti-infective  Neurology  Cardiology  Orthopaedic  Diabology  Gastroenterology  Ophthalmology  Nephrology  Urology  Dermatology  Gynaecology  Respiratory, oncology, dental and nutritionals
POLICIES & PROGRAMS SUN PHARMA has many policies and programs . Some of them are listed below  Whistleblower policy for SPIL & Indian Subsidiaries  Whistleblower policy for Global Subsidiaries  Ranbaxy Disclosure program  Ranbaxy Disclosure policy.
COMPETITORS SUN PHARMA has large number of competitors throughout the world . Some of them are mentioned here and they will be briefed in upcoming slides
LUPIN PHARMACEUTICALS RANKING - 2ND INCORPORATED - 1968 CEO - VINITA GUPTA STOCK PRICE - ₹1877.80 REGISTERED OFFICE - MUMBAI FACTORY/PLANT - THANE , MADHYA PRADESH, GUJARAT, AURANGABAD, PUNE, GOA, JAMMU, NAGPUR PRODUCTS PRODUCED - CARDIOLOGY, ORTHOPEDIC, NEUROLOGY , DIABOLOGY, GASTROENTEROLOGY, OPTHALMOLOGY, NEUROLOGY
BOARD OF DIRECTORS-LUPIN  DESH BANDHU GUPTA – CHAIRMAN  KAMAL K SHARMA – VICE CHAIRMAN  M D GUPTA – EXECUTIVE DIRECTOR  NILESH GUPTA – MANAGING DIRECTOR  VINITA GUPTA – CEO  K U MADA – DIRECTOR  R A SHAH - DIRECTOR  VIJAY KELKAR – DIRECTOR  RICHARD ZAHN – DIRECTOR  R V SATAM – COMPANY SECRETARY  DILEEP C CHOKSI – DIRECTOR  SREERAM PADMANABHAN – DIRECTOR
DR.REDDY’S LABORATORIES RANKING - 3RD INCORPORATED - 1984 CEO - G.V.PRASAD STOCK PRICE - ₹4227.40 REGISTERED OFFICE - TELENGANA FACTORY/PLANT - TELENGANA , ANDHRA PRADESH, PONDICHERRY , HIMACHAL PRADESH PRODUCTS PRODUCED - GASTEROENTEROLOGY , NEUROLOGY , RHEUMATOLOGY , UROLOGY , NEUROLOGY , DERMATOLOGY
BOARD OF DIRECTORS  G.V.PRASAD  JAY KOWLES  SATHISH REDDY  SAUMEN CHAKRABORTY
CIPLA PHARMACEUTICALS RANKING - 4TH INCORPORATED – 1935 CEO - SUBHANU SAXENA STOCK PRICE - ₹697.40 REGISTERED OFFICE - MAHARASHTRA FACTORY/PLANT - KARNATAKA , GOA , SIKKIM , HIMACHAl MADHYA PRADESH PRODUCTS PRODUCED -GASTEROENTEROLOGY , NEUROLOGY, RHEUMATOLOGY , UROLOGY , NEUROLOGY , DERMATOLOGY
BOARD OF DIRECTORS - CIPLA  DR.K.A.HAMIED – FOUNDER  DR.YUSUF K HAMIED – CHAIRMAN  M.K.HAMIED – NON EXECUTIVE VICE CHAIRMAN  SUBHANU SAXENA – MD & GLOBAL CEO  RADHAKRISHNAN – WHOLETIME DIRECTOR  SAMINA VAZIRALLI – EXECUTIVE DIRECTOR  ASHOK SINHA – NON EXECUTIVE/INDEPENDENT DIRECTORS  DR.PETER MUGYENYI – NON EXECUTIVE/INDEPENDENT DIRECTORS  ADIL ZAINULBHAI – NON EXECUTIVE/INDEPENDENT DIRECTORS  PUNITA LAL – NON EXECUTIVE/INDEPENDENT DIRECTORS
AUROBINDO PHARMA RANKING : 5TH INCORPORATED : 1986 CEO : ARAVIND VASUDEVA STOCK PRICE : ₹804.40 REGISTERED OFFICE : TELENGANA FACTORY/PLANT : TELENGANA , ANDHRA PRADESH , TAMILNADU ,RAJASTHAN PRODUCTS PRODUCED : GASTEROENTEROLOGY , NEUROLOGY , RHEUMATOLOGY , UROLOGY , NEUROLOGY , DERMATOLOGY
BOARD OF DIRECTORS-AUROBINDO  K. RAGHUNANTHAN – INDEPENDENT & NON EXECUTIVE DIRECTOR  K.NITHYANANDA REDDY – WHOLETIME DIRECTOR & VICE CHAIRMAN  PV.RAMAPRASAD REDDY – NON EXECUTIVE DIRECTOR  M.SIVAKUMARAN – WHOLETIME DIRECTOR  M.MADHAN MOHAN REDDY – WHOLETIME DIRECTOR  N.GOVINDARAJAN – MANAGING DIRECTOR  M.SITARAMA MURTHY – INDEPENDENT DIRECTOR  D.RAJAGOPALA REDDY – INDEPENDENT DIRECTOR  P.SARATH CHANDRA REDDY – NON EXECUTIVE DIRECTOR  DR.AVNIT BIMAL SINGH – INDEPENDENT DIRECTOR
CADILA PHARMA RANKING – 6TH INCORPORATED – 1951 CEO – DR.RAJIV I . MODI STOCK PRICE -RS.1827.35 REGISTERED OFFICE - GUJARAT FACTORY/PLANT – GUJARAT , GOA , MAHARASHTRA, HIMACHAL PRADESH PRODUCTS PRODUCED- NATURAL STREPTOKINASE , HYALURONIC ACID , CARDIOVASCULAR DISEASES
BOARD OF DIRECTORS – CADILA  RAJIV I MODI S– CHAIRMAN & MD  INDRAVADAN AMBALAL MODI – FOUNDER  SHREYAS PARIKH – COMPANY SECRETARY  SHILABEN I MODI – BOARD OF DIRECTORS  PRADIP N KHANDWALLA – BOARD OF DIRECTORS  DN. KHURANA – BOARD OF DIRECTORS  SANJAY SINHA – BOARD OF DIRECTORS
ENTRIES OF PHARMA COMPANIES COMPANIES - YEAR CIPLA - 1935 CADILA PHARMA - 1951 LUPIN PHARMACEUTICALS - 1968 ALKEM LABORATORIES - 1973 MICRO LABS - 1973 NMC HEALTHCARE - 1975 INTAS PHARMACEUTICALS - 1976 SUN PHARMACEUTICALS - 1983 AUROBINDO PHARMA - 1986 ASTER DM HEALTHCARE - 1987 DIVI’S LABORATORIES - 1990 MANKIND PHARMACEUTICALS - 1995
EXIT OF PHARMA COMPANIES  ADVANCE LIFE SCIENCE EXIT – MAY 2009 REASON – THEY COULD NOT OBTAIN RESPONSE FROM US FOOD & DRUG ADMINISTRATION FOR TREATMENT OF PNEUMONIA  ALTAIR THERAUPETIC INC EXIT – 2009 REASON – SINCE THE INHALED ANTISENSE ASTHMA DRUG DIDN’T SHOW ANY BENEFIT  AMBRILIA BIOPHARMA EXIT – 2008 REASON – TRIALS FOR A DRUG TO TREAT ACROMEGALY WAS PUT ON HOLD BY MERCK FOR LONG YEARS  ARYx THERAUPETICS EXIT - 2010 REASON – SINCE THE BLOOD CLOTTING COMPOUND SHOWED NO IMPROVEMENT AND FDA DELAYED IN GIVING LICEMSE  PHENOMIX CORPORATION EXIT – 2010 REASON – FOREST LAB WITHDREW ITS DEAL
EXIT OF COMPANIES (CONTD)  PEPTIMUNE EXIT – REASON – SINCE MERCK SERENO BOUGHT THE FULL RIGHTS OF PI-2301  TOLERX EXIT – 2007 REASON – THE DRUG NAMED OTELIXIZUMAB DIDN’T SHOW ANY POSITIVE DEVELOPMENT  TRANSDEL PHARMACEUTICALS EXIT – REASON - WENT TO BANKRUPTCY AFTER SLOW DECLINE OF OTS PRODUCTS
MERGERS OF PHARMA COMPANIES DEFINITION : THE COMBINING OF TWO OR MORE CMPANIES , GENERALLY BY OFFERING THE STOCKHOLDERS OF ONE COMPANY’S SECURITIES IN THE AQUIRING COMPANY IN EXCHANGE FOR THE SURRENDER OF THEIR STOCK
TYPES OF MERGERS Horizontal merger  Horizontal merger is a business consolidation that occurs between firms who operate in the same space, often as competitors offering the same good or service. Vertical Merger  A vertical merger occurs when two or more firms, operating at different levels within an industry's supply chain, merge operations. Most often the logic behind the merger is to increase synergies created by merging firms that would be more efficient operating as one. Conglomerate merger  A merger between firms that are involved in totally unrelated business activities. There are two types of conglomerate mergers: pure and mixed. Pure conglomerate mergers involve firms with nothing in common, while mixed conglomerate mergers involve firms that are looking for product extensions or market extensions.
EXAMPLES OF MERGERS YEAR ANNOUNCED ACQUIRER/RESULTANT COMPANY TARGET/MERGING COMPANIES ANNOUNCEDTOTAL VALUE($.bn) 2000 GLAXOSMITHKLI NE SMITHKLINEBEECHA M+ GLAXO WELLCOME 72.4 1998 ASTRAZENECA ASTRA+ZENECA 30.4 1996 NOVARTIS CIBA-GEIGY+SANDOZ 29 1999 PHARMACIA PHARMACIA&UPJOH N+ MONSANTO 25.2
ACQUISITION OF PHARMA COMPANIES DEFINITION : When one company takes over another and clearly established itself as the new owner TYPES OF ACQUISITION  . Friendly Acquisition: Both the companies approve of the acquisition under friendly terms.  Reverse Acquisition: A private company takes over a public company.  Back flip Acquisition: The purchasing company becomes a subsidiary of the purchased company
EXAMPLES OF AQUISITION Announced Date Value in $ million Acquirer Acquired Firm Name Country Name Target nation 18 Feb 2014 28,407 Actavis plc United States Forest Laboratories Inc United States 22 April 2014 54,652. Valeant Pharmaceuticals International Inc Canada Allergan Inc United States 22 April 2014 23,050 Novartis AG, GlaxoSmithKline plc Switzerland, United Kingdom GlaxoSmithKline's oncology portfolio, R&D activities & AKT inhibitor rights / Novartis' vaccines business United Kingdom 6 May 2014 14,200 Bayer AG Germany Merck & Co Inc (Consumer Care Business) United States 20 June 2014 56,064.4 AbbVie Inc United States Shire plc United Kingdom 30 June 2013 10,248.2 Amgen Inc United States ONYX Pharmaceuticals Inc United States 19 May 2011 13,682 Takeda Pharmaceutical Co Ltd Japan Nycomed SCA SICAR Switzerland 21 July 2011 35,017.9 Express Scripts Inc United States Medco Health Solutions Inc United States 21 November 2011 11,017.1 Gilead Sciences Inc United States Pharmasset Inc United States 29 August 2010 24,476.7 Sanofi-Aventis SA France Genzyme Corp United States
TAKE-OVERS DEFINITION When an acquiring company makes a bid for a target company. If the takeover goes through, the acquiring company becomes responsible for all of the target company’s operations, holdings and debt. When the target is a publicly traded company, the acquiring company will make an offer for all of the target’s outstanding shares.
TYPES OF TAKE-OVERS TYPES OF TAKE-OVERS :  'Friendly Takeover' - the company bidding will approach the directors of the other company to discuss and agree an offer before proposing it to the shareholders of that company. The bidding company will also have an opportunity to look at the accounts of the business they want to buy - a process known as due diligence.  'Hostile Takeover' - the company bidding has their offer rejected or does not approach the board of the company they wish to buy before making an offer to shareholders. This also means they will not have access to private information about the company - increasing the risk of the takeover. Banks are usually more cautious about lending money for hostile takeovers.  'Reverse Takeover' - the final common type of takeover is the reverse takeover. This happens when a private (not traded on the stock market) company buys a publicly- traded company as a means of acquiring public status without having to list itself
EXAMPLES OF TAKE-OVERS  ZS PHARMA ACQUIRED ACTELION  PFIZER AQUIRED GSK’S MENINGOCOCCAL ACWY VACCINES  HORIZON PHARMA OF IRELAND ACQUIRED DEPOMED  MYLAN OF NETHERLAND ACQUIRED PERRIGO  CONCARDIA FROM CANADA ACQUIRED AMDIPHARM MERCURY  US BASED PURDUE PHARMA ACQUIRED TRKA PROGRAM OF VM PHARMA  CIPLA OF INDIA ACQUIRED INVAGEN AND EXELAN  PFIZER AQUIRED HOSPIRA  ALLERGAN TO ACQUIRE AQUESYS  LANNET ACQUIRED UCB’S KREMER URBAN GENERIC UNIT  AMICUS THERAUPETICS AQUIRED SCIODERM  SUCAMPO PHARMACEUTICALS AQUIRED R-TECH UENO
SUCCESSFUL ENTREPRENEURS MR.BINISH CHUDGAR INTAS PHARMACEUTICALS INCORPORATED IN 1976 HEAD OFFICE- AHMEDABAD ESTD.WEALTH - $2.79 BILLION FINISHED FORMULATIONS AND BIOLOGICS MR.PV.RAMPRASAD REDDY AUROBINDO PHARMA INCORPORATED IN 1986 HEAD OFFICE – HYDRABAD ESTD.WEALTH - $2.26 BILLION BULK AND FINISHED GOODS MR.MURALI.K.DIVI DIVI’S LABORATORIES INCORPORATED IN 1990 HEAD OFFICE – HYDERABAD ESTD.WEALTH - $1.93 BILLION APIs AND INTERMEDIATES
SUCCESSFUL ENTERPRENEUR(Contd.) MR.SAMPRADA SINGH ALKEM LABORATORIES INCORPORATED IN 1973 HEAD OFFICE – MUMBAI ESTD.WEALTH - $1.69 BILLION PHARMACEUTICAL FINISHED FORMULATIONS DR.AZAD MOOPEN ASTER DM HEALTHCARE INCORPORATED IN 1987 HEAD OFFICE – KOCHI ESTD.WEALTH - $1.54 BILLION HOSPITALS AND DIAGNOSTIC CENTRES MR.DILIP SURANA MICRO LABS INCORPORATED IN 1973 HEAD OFFICE – CHENNAI ESTD.WEALTH- $1.49 BILLION BRANDED DRUGS AND APIs
PRODUCTS OF SUN PHARMA THERAUPETIC AREAS PRODUCTS NEUROLOGY&PSYCHIATRY ACAMPROL ADCAPONE ALCOLIV AMIXIDE CARDIOLOGY AMLOBET AZTOR EZ AQUAZIDE 12.5 ANGIZEM 30 ORTHOPAEDIC BENZADAY 15 GASTEROENTEROLOGY ALCAINE-MPS 200ML 1 BTL UROLOGY TROFAME XR GYNOCOLOGY AFDURA RESPIRATORY AB PHYLLINE AQUAMET NASAL SPRA AB PHYLLINE SYRUP
BRANDS OF SUN PHARMA THE MAJOR BRANDS OF SUN PHARMA ARE AS FOLLOWS
GOVERNMENT POLICIES ON PHARMA INSUSTRY  PHARMACEUTICAL POLICY 2002  INDUSTRIAL LICENSING  FOREIGN INVESTMENT  FOREIGN TECHNOLOGY AGREEMENTS (FTA)  IMPORTS  PRICING  QUALITY ASPECTS  PHARMA EDUCATION AND TRAINING  NATIONAL PHARMACEUTICAL PRICING POLICY 2012  DRUG POLICY 1986
POLICY MODEL
IMPACT OF REGULATIONS ON PHARMA INDUSTRY RECENT REGULATIONS OF THE GOVERNMENT THAT HAS IMPACT ON THE PHARMA INDUSTRY ARE LISTED BELOW  Move to establish an integrated regulatory system through the constitution of a National Drug Authority so that quality regulation and price control is performed by the same agency  Establishment of pharmacy vigilance centres at national, zonal and regional levels to monitor adverse drug reactions  Move to bring nearly 374 bulk drugs under price control and regulate trade margins  Capability strengthening to monitor clinical trials, including the setting up of the Clinical Trials Registry of India (CTRI)
RECENT REGULATIONS & ITS IMPACT ON SUNPHARMA  National Program for Prevention and Control of Fluorosis (NPPCF)  National Tobacco Control Program (NTCP)  National Program for Health Care of the Elderly(NPHCE)  National Leprosy eradication program  Cancer Control Program  Cardio Vascular Diseases Eradication Program
INFLATION DEFINITION: Inflation is the percentage change in the value of the Wholesale Price Index (WPI) on a year-on year basis. It effectively measures the change in the prices of a basket of goods and services in a year. In India, inflation is calculated by taking the WPI as base. CAUSES OF INFLATION: DEMAND PULL INFLATION  Depreciation on rate change  Monetary stimulus to the economy  Fast growth in other countries COST PUSH INFLATION  Component cost  Rising labor cost  Higher indirect taxes  A fall in the exchange rate
Inflation & Its Impacts on Pharma Industry Shift towards a Networked business model. Increasing M&A and alliances Consolidation in the market INCREASE INVESTMENTS & MNC ACTIVITY Seen as the next volume driver, though costs of operation is high due to poor health infrastructure INCREASE REACH IN NON METRO MARKETS Though delayed from its April 2010 implementation date, GST will add significant efficiencies to economy and lead to an overhaul of supply chain GOODS & SERVICES TAX More numbers of patients will be coming in for treatment GROWING INSURANCE Shift towards biotech & speciality therapies, • increased investment in R&D and acute disease segment will sustain strong growth CHANGING DISEASE PROFILE Use of technology & IT for innovation in healthcare delivery • e.g. Mobile clinics HEALTH CARE INNOVATION
DEFLATION DEFINITON: A general decline in prices, often caused by a reduction in the supply of money or credit. Deflation can be caused also by a decrease in government, personal or investment spending. The opposite of inflation, deflation has the side effect of increased unemployment since there is a lower level of demand in the economy, which can lead to an economic depression. Central banks attempt to stop severe deflation, along with severe inflation, in an attempt to keep the excessive drop in prices to a minimum. CAUSES OF DEFLATION:  Change in structure of capital market  Increased productivity  Decrease in currency supplies  Austerity measures
Deflation & its Impacts on Pharma Industry During the time of deflation, pharmaceutical industries face many problems. They are as follows:  Deflation will reduce the Foreign Direct Investments (FDI) because usually none of the investors will invest if there is a deflation in that country. Thus research & development on pharmaceutical sector will be reduced.  Deflation reduces the purchasing power of the people. At the time of inflation, income earned by the people will be reduced. Thus they cant afford to buy costly medicines. Thus the pharma companies have to reduce the price of the medicines. It will create loss to the company.  During deflation, the share prices of the pharmaceutical companies will be reduced. It will affect the global market scenario.  At the time of deflation, Government will reduce all the subsidies given to the pharmaceutical companies for research & development.
RECESSION DEFINITION: A significant decline in the activity across the economy, lasting longer than a few months. It is visible in industrial production, employment, real income, and wholesale retail trade. The technical indicator of a recession is two consecutive quarters of negative economic growth as measured by a country’s GDP. EFFECTS OF RECESSION:  Uncertain exchange rate and a sudden increase in dollar value against indian rupees.  Delayed payment  Pharmaceutical products also doesn’t decrease.
STOCK MARKET Stock market is the place where the shares are being traded by the people and the companies. The main regulatory of the stock market is SECURITIES EXCHANGE BOARD OF INDIA (SEBI). SECURITIES EXCHANGE BOARD OF INDIA The following are some of the functions of SEBI. They are:  Protective function It Checks Price Rigging It Prohibits Insider trading SEBI prohibits fraudulent and Unfair Trade Practices  Development function Training to intermediaries promotional activities  Regulatory function framed rules and regulations restrictive on private placements conducts inquiries
SUN PHARMA – STOCK MARKET PROFILE
STOCK MARKET (as on 09/10/2015)
REGULATORY OF PHARMA INDUSTRY OBJECTIVE OF THE REGULATORY: The present study describes a brief review of various regulatory bodies of major developed and developing countries around the world and the scope and challenges of such pharmaceutical regulatory organizations in delivery of safe and effective healthcare products MAJOR REGULATORY OF PHARMA INDUSTRY The major regulatory of pharma industry in India is CENTRAL DRUG STANDARD CONTROL ORGANISATION
REGULATORY AUTHORITY Country Name of Regulatory Authority USA Food and Drug Administration (FDA) UK Medicines and Healthcare Products Regulatory Agency (MHRA) Australia Therapeutic Goods Administration (TGA) India Central Drug Standard Control Organization (CDSCO) Canada Health Canada Europe European Medicines Agency (EMEA) Denmark Danish Medicines Agency Costa Rica Ministry of Health New Zealand Medsafe - Medicines and Medical Devices Safety Authority Sweden Medical Products Agency (MPA) Netherlands Medicines Evaluation Board Ireland Irish Medicines Board Italy Italian Pharmaceutical Agency Nigeria National Agency for Food and Drug Administration and Control (NAFDAC) Ukraine Ministry of Health Singapore Centre for Pharmaceutical Administration Health Sciences Authority Hong Kong Department of Health: Pharmaceutical Services Paraguay Ministry of Health Sweden Medical Products Agency (MPA) Thailand Ministry of Public Health China State Food and Drug Administration Germany Federal Institute for Drugs and Medical Devices Malaysia National Pharmaceutical Control Bureau,Ministry of Health Pakistan Drugs Control Organization, Ministry of Health South AfricaMedicines Control Council Sri Lanka SPC,Ministry of Health
CONCLUSION INDIAN PHARMACEUTICAL INDUSTRY PLAYS A MAJOR ROLE IN INDUSTRIAL SECTOR IN DEVELOPING THE COUNTRY AS WELL AS MAKING THE WHOLE WORLD MARKET TO TURN AROUND TO SEE OUR COUNTRY. SUN PHARMACEUTICALS HAS A MAJOR PART IN DEVELOPMENT OF INDIAN PHARMACEUTICAL INDUSTRY BY PRODUCING DRUGS FOR MAJOR THERAUPETIC TREATMENTS WHICH IS SUPPORTED BY MORE THAN 150 COUNTRIES AND 5 CONTINENTS. IT IS EXPECTED THAT SUN PHARMA WILL BECOME TOP 1ST PHARMACEUTICAL COMPANY IN THE WORLD MARKET BY 2020.

More Related Content

PPTX
Marketing Strategy of Sun Pharmaceuticals
byAman Dube
 
PDF
Sunpharma present13
byCompany Spotlight
 
PPTX
Indian pharmaceutical industry organisational structure & strategies
byPankaj Gaurav
 
PPTX
Sun pharma Presentation
byshivsharanjak
 
PDF
Sun pharma financial analysis 2008-2017
byKushal Shah
 
PDF
Sun pharma- A complete company review, analysis of crisis and realistic recom...
byTilikaChawda
 
PPTX
SWOT Analysis of Sunpharma
byPratik Rahate
 
PPTX
Marketing strategies adopted by Bajaj auto
byRahulKaushik108
 
Marketing Strategy of Sun Pharmaceuticals
byAman Dube
 
Sunpharma present13
byCompany Spotlight
 
Indian pharmaceutical industry organisational structure & strategies
byPankaj Gaurav
 
Sun pharma Presentation
byshivsharanjak
 
Sun pharma financial analysis 2008-2017
byKushal Shah
 
Sun pharma- A complete company review, analysis of crisis and realistic recom...
byTilikaChawda
 
SWOT Analysis of Sunpharma
byPratik Rahate
 
Marketing strategies adopted by Bajaj auto
byRahulKaushik108
 

What's hot

PDF
Why Should the Doctor Rx Your Product?
byAnup Soans
 
ODP
Sun pharma
byRavinder Sharma
 
PPTX
Sun pharma ppt
byUnitedworld School Of Business
 
PDF
Mankind corporate presentation
byAnkit Khandelewal
 
PPTX
Marketing research on maruti suzuki
byjairane355
 
PPTX
Cipla ppt presentation By Ajit R. Kulkarni
byAjit Kulkarni
 
PPTX
Capital Structure of Tata Motors
byAkash Saha
 
PPTX
Presentation on maruti suzuki
bySURAJ KUMAR MEHER
 
PPTX
Glenmark pharma ppt final
bySuraj Warthy
 
PDF
Project report marketing- abott
byStudsPlanet.com
 
PPTX
Rosuvastatin final marketing plan
byAsiful alam
 
PPTX
Marketing mix of sun pharma
byAishwaryaMurali16
 
PPTX
Sun pharma
byMonika Lohia
 
PPTX
Final ppt
byms987778
 
PPTX
Patanjali Ayurved -Marketing Strategy (4P's)
bySayan Mukherjee
 
DOCX
Marketing ayurveda
byBetsy Booboo
 
PPTX
Cipla Presentation
byKartik Maniktala
 
PPT
Distribution Channel Itc
byhh
 
PDF
The Mankind Pharma Story by Dr. Sumit Ghoshal
byAnup Soans
 
PDF
Sun pharma Industries limited at a Glance
byMithlesh Jha
 
Why Should the Doctor Rx Your Product?
byAnup Soans
 
Sun pharma
byRavinder Sharma
 
Sun pharma ppt
byUnitedworld School Of Business
 
Mankind corporate presentation
byAnkit Khandelewal
 
Marketing research on maruti suzuki
byjairane355
 
Cipla ppt presentation By Ajit R. Kulkarni
byAjit Kulkarni
 
Capital Structure of Tata Motors
byAkash Saha
 
Presentation on maruti suzuki
bySURAJ KUMAR MEHER
 
Glenmark pharma ppt final
bySuraj Warthy
 
Project report marketing- abott
byStudsPlanet.com
 
Rosuvastatin final marketing plan
byAsiful alam
 
Marketing mix of sun pharma
byAishwaryaMurali16
 
Sun pharma
byMonika Lohia
 
Final ppt
byms987778
 
Patanjali Ayurved -Marketing Strategy (4P's)
bySayan Mukherjee
 
Marketing ayurveda
byBetsy Booboo
 
Cipla Presentation
byKartik Maniktala
 
Distribution Channel Itc
byhh
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
byAnup Soans
 
Sun pharma Industries limited at a Glance
byMithlesh Jha
 

Viewers also liked

PPTX
“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY”
byDharmik Bhatt
 
PDF
Overview of the Pharma industry
bykeyursavalia
 
PPTX
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
bySabarinath Suryaprakash
 
PPTX
Pharma industry 1-4_9_29_50
bydomsr
 
PPT
Strategic implementation presentation
bySofiadora Drahman
 
PPTX
Supply Chain Management Glenmark Pharma
byAbhishek Dhamankar
 
PDF
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
byIrish Pereira
 
PDF
6 SWOT Analysis Examples to Help You Write Your Own
byPalo Alto Software
 
“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY”
byDharmik Bhatt
 
Overview of the Pharma industry
bykeyursavalia
 
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
bySabarinath Suryaprakash
 
Pharma industry 1-4_9_29_50
bydomsr
 
Strategic implementation presentation
bySofiadora Drahman
 
Supply Chain Management Glenmark Pharma
byAbhishek Dhamankar
 
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...
byIrish Pereira
 
6 SWOT Analysis Examples to Help You Write Your Own
byPalo Alto Software
 

Similar to SUN PHARMA & PHARMA INDUSTRY 2015

PPSX
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...
bysridivyaannavarapu
 
PPTX
cipla and sun pharma
byAkash Gawande
 
PPTX
PRITI.pptx
byPritiMittal8
 
PPTX
Pharmaceutical Industries
byNaina Dubey
 
PPTX
Analysis of Pharmaceutical Sector in India
byAkshay Krishnapurkar
 
PPT
Pharmaceutical industry in india
bySomnath Surai
 
PPTX
Present Status and Scope of Pharmaceutical industry in India
byMadhuraNewrekar
 
PPTX
Pharmaceutical Industry Global & Indian
byprateek_floyd
 
PPTX
Equity project
bySaurabh Mittra
 
PPTX
Equity Project
bySaurabh Mittra
 
DOCX
Equity research report himanshi and rashmi
byHimanshiKarmakar1
 
PPTX
Industry analysis
byKanchuki Sarma
 
PPTX
Business development of sunpharma presentation 3.pptx
bydmrjput
 
PDF
Pharmaceutical industry-in-india
byChandresh M
 
PDF
Indian companies are taking center stage in Complex Generics at US and EU mar...
bympadvisors
 
PPTX
International Business
bychaityamehta2
 
PPTX
Top pharmaceutical company
byPramod Kumar Sah
 
PDF
Brief Report on the Indian Pharmaceutical Industry - 2011
bydavid_singer
 
PDF
SPIL-IR-Presentation-September-2022-INR.pdf
byMOHAMMED YASER HUSSAIN
 
PPTX
Strategic Management Assignment Presentation on Competitor Analysis in Pharma...
byWaliaFatima3
 
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...
bysridivyaannavarapu
 
cipla and sun pharma
byAkash Gawande
 
PRITI.pptx
byPritiMittal8
 
Pharmaceutical Industries
byNaina Dubey
 
Analysis of Pharmaceutical Sector in India
byAkshay Krishnapurkar
 
Pharmaceutical industry in india
bySomnath Surai
 
Present Status and Scope of Pharmaceutical industry in India
byMadhuraNewrekar
 
Pharmaceutical Industry Global & Indian
byprateek_floyd
 
Equity project
bySaurabh Mittra
 
Equity Project
bySaurabh Mittra
 
Equity research report himanshi and rashmi
byHimanshiKarmakar1
 
Industry analysis
byKanchuki Sarma
 
Business development of sunpharma presentation 3.pptx
bydmrjput
 
Pharmaceutical industry-in-india
byChandresh M
 
Indian companies are taking center stage in Complex Generics at US and EU mar...
bympadvisors
 
International Business
bychaityamehta2
 
Top pharmaceutical company
byPramod Kumar Sah
 
Brief Report on the Indian Pharmaceutical Industry - 2011
bydavid_singer
 
SPIL-IR-Presentation-September-2022-INR.pdf
byMOHAMMED YASER HUSSAIN
 
Strategic Management Assignment Presentation on Competitor Analysis in Pharma...
byWaliaFatima3
 

More from Sabarinath Suryaprakash

PPTX
Training need analysis
bySabarinath Suryaprakash
 
PPTX
Export & Import - Procedure and Documentation
bySabarinath Suryaprakash
 
PPTX
Dabbawallas- The Successful Managers
bySabarinath Suryaprakash
 
PPTX
Hr portion
bySabarinath Suryaprakash
 
PPTX
Factories act
bySabarinath Suryaprakash
 
PPTX
Big data
bySabarinath Suryaprakash
 
PPTX
Responsibility accounting
bySabarinath Suryaprakash
 
PPTX
Input devices of a computer
bySabarinath Suryaprakash
 
PPTX
harish bhatt case study
bySabarinath Suryaprakash
 
PPTX
Motivation theory
bySabarinath Suryaprakash
 
Training need analysis
bySabarinath Suryaprakash
 
Export & Import - Procedure and Documentation
bySabarinath Suryaprakash
 
Dabbawallas- The Successful Managers
bySabarinath Suryaprakash
 
Hr portion
bySabarinath Suryaprakash
 
Factories act
bySabarinath Suryaprakash
 
Big data
bySabarinath Suryaprakash
 
Responsibility accounting
bySabarinath Suryaprakash
 
Input devices of a computer
bySabarinath Suryaprakash
 
harish bhatt case study
bySabarinath Suryaprakash
 
Motivation theory
bySabarinath Suryaprakash
 

Recently uploaded

PPTX
L5 DRG Pulsed Radiofrequency ablation.pptx
bySandeep Margan
 
PPTX
Centrifugation pharmaceutical engineering
byShraddha Bandgar
 
PDF
RESPIRATORY_SYSTEM_ ANATOMY_PATHOPHYSIOLOGY
bygovt. college of nursing bikaner
 
PPTX
4. Nursery raising of vegetable crops.pptx
byUmeshTimilsina1
 
PPTX
Salesforce Spring 26` Release Key Features.pptx
byMehediHasan939830
 
PPT
Blood Grouping.ppt - Hematology -Physiology
bykishorkumar396
 
PPTX
Cultivation practice of Cucumber, Pumpkin and summer squash in Nepal.pptx
byUmeshTimilsina1
 
PPTX
Cultivation Practice of Chilli and sweet Pepper.pptx
byUmeshTimilsina1
 
PPTX
Introduction to Mendelian inheritance.pptx
bypramodphirke1
 
PDF
Renewable Energy Resources Unit 2 Easy notes (EduShine Classes).pdf
byaaquib913
 
PPTX
Cultivation Practice of Major Cole crops in Nepal.pptx
byUmeshTimilsina1
 
PPTX
All Things 2025 - A Year in Review Quiz!
byShashank Jogani
 
PDF
Gaming Quiz 2025- 27th October 2025, Quiz Club NITW
byQuiz Club NITW
 
PPTX
How to Setup Global Invoice in Odoo 19 POS
byCeline George
 
PDF
W.B. Yeats: The Visionary & The Observer A Comprehensive Study of 'The Second...
bykrutivyas2005
 
PPTX
1. Importance, scope and constraints of vegetable and spice crop production i...
byUmeshTimilsina1
 
PDF
Result Analysis of the Pre Board 2025 .pdf
byDirectorate of Education Delhi
 
PPTX
Cultivation Practice of Tomato in Nepal.pptx
byUmeshTimilsina1
 
PPTX
Non aqueous titration First Year B. Pharm.pptx
byMs. Ashatai Patil
 
PPTX
2. Classification of vegetable and spice crops.pptx
byUmeshTimilsina1
 
L5 DRG Pulsed Radiofrequency ablation.pptx
bySandeep Margan
 
Centrifugation pharmaceutical engineering
byShraddha Bandgar
 
RESPIRATORY_SYSTEM_ ANATOMY_PATHOPHYSIOLOGY
bygovt. college of nursing bikaner
 
4. Nursery raising of vegetable crops.pptx
byUmeshTimilsina1
 
Salesforce Spring 26` Release Key Features.pptx
byMehediHasan939830
 
Blood Grouping.ppt - Hematology -Physiology
bykishorkumar396
 
Cultivation practice of Cucumber, Pumpkin and summer squash in Nepal.pptx
byUmeshTimilsina1
 
Cultivation Practice of Chilli and sweet Pepper.pptx
byUmeshTimilsina1
 
Introduction to Mendelian inheritance.pptx
bypramodphirke1
 
Renewable Energy Resources Unit 2 Easy notes (EduShine Classes).pdf
byaaquib913
 
Cultivation Practice of Major Cole crops in Nepal.pptx
byUmeshTimilsina1
 
All Things 2025 - A Year in Review Quiz!
byShashank Jogani
 
Gaming Quiz 2025- 27th October 2025, Quiz Club NITW
byQuiz Club NITW
 
How to Setup Global Invoice in Odoo 19 POS
byCeline George
 
W.B. Yeats: The Visionary & The Observer A Comprehensive Study of 'The Second...
bykrutivyas2005
 
1. Importance, scope and constraints of vegetable and spice crop production i...
byUmeshTimilsina1
 
Result Analysis of the Pre Board 2025 .pdf
byDirectorate of Education Delhi
 
Cultivation Practice of Tomato in Nepal.pptx
byUmeshTimilsina1
 
Non aqueous titration First Year B. Pharm.pptx
byMs. Ashatai Patil
 
2. Classification of vegetable and spice crops.pptx
byUmeshTimilsina1
 

SUN PHARMA & PHARMA INDUSTRY 2015

  • 1.
    ERVAS PHARMACEUTICALS HAVE NATURALLIVE NATURAL MISSION: ERVAS’ MISSION IS TO MAKE HERBAL -WELLNESS A PART OF EVERY HOME AND TO CREATE BELIEF THAT GOOD HEALTH SHOULD BE ACCESSIBLE TO EVERYONE
  • 2.
    GROUP MEMBERS PRAVEEN KUMAR AZHARDEEN SABARINATHD.S SYED MOHAMMED MOHAMED ABUBACKER vIGNESHWARAN
  • 3.
  • 4.
    PHARMACEUTICAL INDUSTRY  The IndianPharmaceutical Industry currently tops the chart amongst India’s Science based Industries with wide ranging capabilities in the complex field of drug manufacture and technology.  A highly organized sector, the Indian Pharmaceutical Industry is expected to expand at a CAGR of 23.9% by 2020.  It ranks very high among all the third world countries, in terms of technology, quality and the vast range of medicines that are manufactured
  • 5.
    DEVELPOMENT OF PHARMACEUTICAL INDUSTRYIN INDIA  INDIAN PHARMACEUTICAL MARKET HAS REACHED 10TH PLACE IN THE WORLD MARKET
  • 6.
    INCREMENTAL GROWTH OFINDIA-2015 INDIAN PHARMACEUTICAL INDUSTRY HAS REACHED TOP 3RD IN INCREMENTAL GROWTH OF THE SECTOR AS COMPARED TO US(1ST PLACE) AND CHINA(2ND PLACE)
  • 7.
    CAGR REPORT-2015 ONINDIAN PHARMA MARKET  INDIAN PHARMA MARKET IS LIKELY TO TRIPLICATE BY 2015
  • 8.
     Between 2012-2018,the “patent cliff" will wipe an estimated $148 billion off pharmaceuticals industry revenues due to many drugs coming out of patents  Rising cost of R&D, the cost of bringing a molecule to market globally is estimated to be from $800 million to $4 billion.  On average, out of every 10,000 molecules been developed; only one or two are likely to reach the market.  Increasing government pressure, with harsher price controls and taxes.  European Medical Agency (EMA) and the US Food and Drug Administration (USFDA) are focusing on risk management; thereby putting pressures on profitability of pharmaceutical companies. Issues for the Industry
  • 9.
    SWOT Analysis OfIndian Pharmaceutical Industry Strengths Weaknesses Opportunities Threats •Low cost of skilled manpower •Access to large pool of highly trained scientists •Strong marketing and distribution network •Proven track record in design of high technology manufacturing devices •Low cost of innovation, manufacturing and operations •Stringent pricing regulations •Poor transport and medical infrastructure •Lack of data protection •Very competitive environment •Poor health insurance coverage •Production of low quality drugs tarnishes image of industry abroad •Low investment in innovative R&D •Increase in per capita income •Global demand for generics rising •Increasing population with more sedentary lifestyle •Increasing health insurance sector •Significant investment from MNCs •Medical tourism •Cheap, diverse clinical trials •Global outsourcing hub due to low cost of skilled labor •Other low cost countries affecting demand •Government regulations changing •Expanding of Drugs Price Control Order •Lack of investment in infrastructure •Wage inflation •R&D restricted by lack of animal testing and outdated patient office •Counterfeiting threat
  • 10.
    GENERIC INDUSTRY THE FOLLOWINGARE SOME OF THE GENERIC DRUG MANUFACTURERS  Actavis  Acura pharmaceuticals  Apotex  Aspen Pharmacare  Bio pharma  EMS  Galex  Getz pharma  Hikma Pharmaceuticals  Hospira  Incepta Phamraceuticals  Medinfar  North China pharmaceuticals group corp  Perrigo  Ranbaxy Laboratories  Saidal  Simcere Pharmaceuticals  Stada Arzneimittrl  Sun Pharmaceuticals  Synthon  Teva Pharmaceuticals  Torque Pharmaceuticals
  • 11.
    NON GENERIC INDUSTRY THEFOLLOWING ARE SOME OF THE NON GENERIC INDUSRTRY IN PHARMACEUTICAL SECTOR  GLENMARK  ABOTT INDIA  BIOCON  ALEMBIC PHARMA  SANOFI INDIA  WOCKHARDT  PFIZER  NECTAR LIFE  AJANTA PHARMA  SHARON BIO MEDI  GRANULES INDIA  UNICHEM LABS  AARTI DRUGS
  • 12.
    132 4.1 0 2 4 6 8 10 12 14 16 18 20 0 1000 2000 3000 4000 5000 6000 7000 8000 9000 US France UKAustralia Japan Brazil Russia South Africa China India Indonesia kenya Ghana % GDP Per Capita US $ Per Capita Spent on Healthcare % GDP Spent on Healthcare Investment Comparison
  • 13.
    MODE OF ENTRIESOF FOREIGN PHARMAS TO INDIA THE FOLLOWING ARE SOME OF THE FOREIGN MULTINATIONAL PHARMACEUTICAL COMPANIES WHICH CAME TO INDIA THROUGH OUR INDIAN PHARMA COMPANIES . THEY ARE LISTED BELOW. MULTINATIONAL PHARMA - INDIAN PHARMA MERCK & CO - SUN PHARMACEUTICALS PFIZER - AUROBINDO PHARMA, CLARIS LIFESCIENCES STRIDES ARCOLABS GLAXOSMITHKLINE - DR.REDDY’S LABORATORIES ASTRAZENECA - TORRENT PHARMACEUTICALS , INTAS PHARMACEUTICALS , AUROBINDO PHARMA DAICHII SANKYO - RANBAXY ABOTT - PIRAMAL HEALTHCARE SANOFI AVENTIS - SHANTHA BIOTECH MYLAN - MATRIX RECKITT BENCKISER - PARAS HOSPIRA - ORCHID FRESENIUS KABI - DABUR PHARMA
  • 14.
    MAJOR MEMBERS OFINDIAN PHARMA INDUSTRY The following are the major pharma companies in India . They are  CIPLA  DR.REDDY’S LABS  LUPIN  CADILA HEALTH  TORRENT PHARMA  GLAXOSMITHKLINE  JUBILANT LIFE  IPCA LABS  DIVIS LABS  SUN PHARMA  PIRAMAL ENTER  GLENMARK  ABOTT INDIA  BIOCON  ALEMBIC PHARMA  SANOFI INDIA  WOCKHARDT  PFIZER  NECTAR LIFE  AJANTA PHARMA  SHARON BIO MEDI  GRANULES INDIA  UNICHEM LABS  AARTI DRUGS
  • 15.
    OUR COMPANY OUR PROJECTIS ABOUT THE INDIAN PHARMACEUTICAL GIANT , SUN PHARMACEUTICALS WHY SUN PHARMACEUTICALS ? ACTUALLY IT IS A MILLION DOLLAR QUESTION WHY WE TOOK SUN PHARMA THAN SOME OTHER COMPANY? SUN PHARMACEUTICALS IS NOW THE TOP PHARMACUTICAL COMPANY IN INDIA. BUT IN 1983, WHEN MR.DILIP SHANGHVI WHO WAS THE SON OF A DRUG WHOLESALE DEALER , HE SUDDENLY THOUGHT THAT WHY INSTEAD OF DEALING WITH DRUGS , WHY DON’T WE PRODUCE IT?? THIS HAS MADE HIM TO START A PHARMACEUTICAL COMPANY WITH A VERY VERY SMALL CAPITAL OF JUST ₹ 10000 . BUT NOW IT HAS AN ASSET VALUE OF RS.9816 CRORES WITHIN A DECADE. AND MOREOVER , HE HAD MADE THE WHOLE WORLD TO TURN AROUND US AND MADE THEM FEEL THAT THERE IS AN INDIAN PHARMACEUTICAL COMPANY THAT CAN COMPETE THE WORLD MARKET. NOW , SUN PHARMACEUTICALS IS THE TOP 1ST PHARMACEUTICAL COMPANY IN INDIA AND TOP 5TH IN WORLD GENERIC PHARMACEUTICAL MARKET. THIS IS THE MAIN REASON WHY WE TOOK SUN PHARMACEUTICALS
  • 16.
    SUN PHARMACEUTICALS (P)LTD TAG LINE LEADERSHIP THROUGH FOCUSED RESEARCH MISSION MISSION OF GIVING AN IMPETUS TO RESEARCH & DEVELOPMENT IN INDIA VISION TO DEVELOP MEDICAL RESEARCH IN UPCOMING FUTURE
  • 17.
    SUN PHARMACEUTICALS  SUNPHARMACEUTICALS LTD is a multinational Pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and Active Pharmaceutical Ingredients (API) primarily in India and in United States.  The company offers formulations in various therapeutic areas such as cardiology, psychiatry, neurology, gastroenterology and diabology.  It also provides APIs such as warfarin, carbamazepine, etodolac, and clorazepate, as well as anticancer, steroids peptides, sex hormones and controlled substances  Pharmaceutical Giant SUN PHARMACEUTICALS LIMITED (NET PROFIT OF ₹ 2,828 CRORE IN FY14-15) has topped as No.1 Pharmaceutical Industry in India in 2015 against its best rivals CIPLA LABORATORIES (NET PROFIT OF ₹ 1,181 CRORE), LUPIN LABS (NET PROFIT OF ₹ 2,397 CRORES) DR.REDDY’S LABORATORIES (NET PROFIT OF ₹ 1,679 CRORES) AND ETC..
  • 18.
    HISTORY OF THECOMPANY  Established by MR.DILIP SHANGHVI in 1983 in VAPI with five products to treat psychiatry ailments.  Cardiology products were introduced in 1987 followed by Gastroenterology products in 1989.  Today it is the largest chronic prescription company in India and a market leader in psychiatry, neurology, cardiology, orthopedics, ophthalmology, and gastroenterology and nephrology  At present, SUN PHARMA has a net income of ₹2,828 crores and with Total Asset value of ₹9816 crores and the current market price of a share is ₹927.25 per share (as on 19/08/2015)
  • 19.
    BOARD OF DIRECTORS ISRAELMAKOV DILIP SHANGHVI SUDHIR V. VALIA SAILESH T. DESAI HASMUKH S SHAH KEKI M MISTRY ASHWIN DANI MOHANCHAND
  • 20.
    ACQUISITION & JOINTVENTURES  KNOLL PHARMACEUTICALS & MJ PHARMA – 1996  TAMIL NADU DADHA PHARMACEUTICALS LTD -1997  CARACO PHARMACEUTICALS – 1997  NATCO PHARMA – 1998  MILMET LABS & GUJARAT LYKA ORGANICS – 1999  PRADEEP DRUG COMPANY – 2000  PHLOX PHARMA – 2004  ABLE LABS – 2005  CHATTEM CHEMICALS – 2008  TARO PHARMACEUTICALS – 2010  MSD – 2011  DUSA PHARMACEUTICALS – 2012  INTREXON – 2013  RANBAXY LABORATORIES - 2014
  • 21.
    GLOBAL PRESENCE  Withglobal revenues of over US$ 4.5 billion, SUN PHARMA is the fifth largest specialty generic pharmaceutical company in the world. They provide high quality affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide. Sun pharma also includes the largest and most trusted pharmaceutical company. Their global presence is supported by 45 manufacturing facilities across 5 continents.  In the US market contributes a significant share of or revenues, they are the leader in the generic dermatology segment,. They have strong capabilities in developing generic and complex products with a robust pipeline of 149 ANDAs including high value first-2-file (FTF) opportunities. They have an established presence in Europe and key high growth emerging markets like Russia , Romania , south Africa , brazil and , Malaysia.
  • 22.
    LOCATIONS  HEADQUARTERS –GUJARAT  CORPORATE OFF – MUMBAI  FACTORY PLANTS - Dadra &Nagar havelli Gujarat Maharashtra Kanchipuram Andheri Jammu & Kashmir Ohio – US New jersey – US Michigan –US Bangladesh Hungary Sikkim Mexico
  • 23.
    PRODUCTS PRODUCED They producedrugs for the following categories of treatments. They are  Psychiatry  anti-infective  Neurology  Cardiology  Orthopaedic  Diabology  Gastroenterology  Ophthalmology  Nephrology  Urology  Dermatology  Gynaecology  Respiratory, oncology, dental and nutritionals
  • 24.
    POLICIES & PROGRAMS SUNPHARMA has many policies and programs . Some of them are listed below  Whistleblower policy for SPIL & Indian Subsidiaries  Whistleblower policy for Global Subsidiaries  Ranbaxy Disclosure program  Ranbaxy Disclosure policy.
  • 25.
    COMPETITORS SUN PHARMA haslarge number of competitors throughout the world . Some of them are mentioned here and they will be briefed in upcoming slides
  • 26.
    LUPIN PHARMACEUTICALS RANKING -2ND INCORPORATED - 1968 CEO - VINITA GUPTA STOCK PRICE - ₹1877.80 REGISTERED OFFICE - MUMBAI FACTORY/PLANT - THANE , MADHYA PRADESH, GUJARAT, AURANGABAD, PUNE, GOA, JAMMU, NAGPUR PRODUCTS PRODUCED - CARDIOLOGY, ORTHOPEDIC, NEUROLOGY , DIABOLOGY, GASTROENTEROLOGY, OPTHALMOLOGY, NEUROLOGY
  • 27.
    BOARD OF DIRECTORS-LUPIN DESH BANDHU GUPTA – CHAIRMAN  KAMAL K SHARMA – VICE CHAIRMAN  M D GUPTA – EXECUTIVE DIRECTOR  NILESH GUPTA – MANAGING DIRECTOR  VINITA GUPTA – CEO  K U MADA – DIRECTOR  R A SHAH - DIRECTOR  VIJAY KELKAR – DIRECTOR  RICHARD ZAHN – DIRECTOR  R V SATAM – COMPANY SECRETARY  DILEEP C CHOKSI – DIRECTOR  SREERAM PADMANABHAN – DIRECTOR
  • 28.
    DR.REDDY’S LABORATORIES RANKING -3RD INCORPORATED - 1984 CEO - G.V.PRASAD STOCK PRICE - ₹4227.40 REGISTERED OFFICE - TELENGANA FACTORY/PLANT - TELENGANA , ANDHRA PRADESH, PONDICHERRY , HIMACHAL PRADESH PRODUCTS PRODUCED - GASTEROENTEROLOGY , NEUROLOGY , RHEUMATOLOGY , UROLOGY , NEUROLOGY , DERMATOLOGY
  • 29.
    BOARD OF DIRECTORS G.V.PRASAD  JAY KOWLES  SATHISH REDDY  SAUMEN CHAKRABORTY
  • 30.
    CIPLA PHARMACEUTICALS RANKING -4TH INCORPORATED – 1935 CEO - SUBHANU SAXENA STOCK PRICE - ₹697.40 REGISTERED OFFICE - MAHARASHTRA FACTORY/PLANT - KARNATAKA , GOA , SIKKIM , HIMACHAl MADHYA PRADESH PRODUCTS PRODUCED -GASTEROENTEROLOGY , NEUROLOGY, RHEUMATOLOGY , UROLOGY , NEUROLOGY , DERMATOLOGY
  • 31.
    BOARD OF DIRECTORS- CIPLA  DR.K.A.HAMIED – FOUNDER  DR.YUSUF K HAMIED – CHAIRMAN  M.K.HAMIED – NON EXECUTIVE VICE CHAIRMAN  SUBHANU SAXENA – MD & GLOBAL CEO  RADHAKRISHNAN – WHOLETIME DIRECTOR  SAMINA VAZIRALLI – EXECUTIVE DIRECTOR  ASHOK SINHA – NON EXECUTIVE/INDEPENDENT DIRECTORS  DR.PETER MUGYENYI – NON EXECUTIVE/INDEPENDENT DIRECTORS  ADIL ZAINULBHAI – NON EXECUTIVE/INDEPENDENT DIRECTORS  PUNITA LAL – NON EXECUTIVE/INDEPENDENT DIRECTORS
  • 32.
    AUROBINDO PHARMA RANKING :5TH INCORPORATED : 1986 CEO : ARAVIND VASUDEVA STOCK PRICE : ₹804.40 REGISTERED OFFICE : TELENGANA FACTORY/PLANT : TELENGANA , ANDHRA PRADESH , TAMILNADU ,RAJASTHAN PRODUCTS PRODUCED : GASTEROENTEROLOGY , NEUROLOGY , RHEUMATOLOGY , UROLOGY , NEUROLOGY , DERMATOLOGY
  • 33.
    BOARD OF DIRECTORS-AUROBINDO K. RAGHUNANTHAN – INDEPENDENT & NON EXECUTIVE DIRECTOR  K.NITHYANANDA REDDY – WHOLETIME DIRECTOR & VICE CHAIRMAN  PV.RAMAPRASAD REDDY – NON EXECUTIVE DIRECTOR  M.SIVAKUMARAN – WHOLETIME DIRECTOR  M.MADHAN MOHAN REDDY – WHOLETIME DIRECTOR  N.GOVINDARAJAN – MANAGING DIRECTOR  M.SITARAMA MURTHY – INDEPENDENT DIRECTOR  D.RAJAGOPALA REDDY – INDEPENDENT DIRECTOR  P.SARATH CHANDRA REDDY – NON EXECUTIVE DIRECTOR  DR.AVNIT BIMAL SINGH – INDEPENDENT DIRECTOR
  • 34.
    CADILA PHARMA RANKING –6TH INCORPORATED – 1951 CEO – DR.RAJIV I . MODI STOCK PRICE -RS.1827.35 REGISTERED OFFICE - GUJARAT FACTORY/PLANT – GUJARAT , GOA , MAHARASHTRA, HIMACHAL PRADESH PRODUCTS PRODUCED- NATURAL STREPTOKINASE , HYALURONIC ACID , CARDIOVASCULAR DISEASES
  • 35.
    BOARD OF DIRECTORS– CADILA  RAJIV I MODI S– CHAIRMAN & MD  INDRAVADAN AMBALAL MODI – FOUNDER  SHREYAS PARIKH – COMPANY SECRETARY  SHILABEN I MODI – BOARD OF DIRECTORS  PRADIP N KHANDWALLA – BOARD OF DIRECTORS  DN. KHURANA – BOARD OF DIRECTORS  SANJAY SINHA – BOARD OF DIRECTORS
  • 36.
    ENTRIES OF PHARMACOMPANIES COMPANIES - YEAR CIPLA - 1935 CADILA PHARMA - 1951 LUPIN PHARMACEUTICALS - 1968 ALKEM LABORATORIES - 1973 MICRO LABS - 1973 NMC HEALTHCARE - 1975 INTAS PHARMACEUTICALS - 1976 SUN PHARMACEUTICALS - 1983 AUROBINDO PHARMA - 1986 ASTER DM HEALTHCARE - 1987 DIVI’S LABORATORIES - 1990 MANKIND PHARMACEUTICALS - 1995
  • 37.
    EXIT OF PHARMACOMPANIES  ADVANCE LIFE SCIENCE EXIT – MAY 2009 REASON – THEY COULD NOT OBTAIN RESPONSE FROM US FOOD & DRUG ADMINISTRATION FOR TREATMENT OF PNEUMONIA  ALTAIR THERAUPETIC INC EXIT – 2009 REASON – SINCE THE INHALED ANTISENSE ASTHMA DRUG DIDN’T SHOW ANY BENEFIT  AMBRILIA BIOPHARMA EXIT – 2008 REASON – TRIALS FOR A DRUG TO TREAT ACROMEGALY WAS PUT ON HOLD BY MERCK FOR LONG YEARS  ARYx THERAUPETICS EXIT - 2010 REASON – SINCE THE BLOOD CLOTTING COMPOUND SHOWED NO IMPROVEMENT AND FDA DELAYED IN GIVING LICEMSE  PHENOMIX CORPORATION EXIT – 2010 REASON – FOREST LAB WITHDREW ITS DEAL
  • 38.
    EXIT OF COMPANIES(CONTD)  PEPTIMUNE EXIT – REASON – SINCE MERCK SERENO BOUGHT THE FULL RIGHTS OF PI-2301  TOLERX EXIT – 2007 REASON – THE DRUG NAMED OTELIXIZUMAB DIDN’T SHOW ANY POSITIVE DEVELOPMENT  TRANSDEL PHARMACEUTICALS EXIT – REASON - WENT TO BANKRUPTCY AFTER SLOW DECLINE OF OTS PRODUCTS
  • 39.
    MERGERS OF PHARMACOMPANIES DEFINITION : THE COMBINING OF TWO OR MORE CMPANIES , GENERALLY BY OFFERING THE STOCKHOLDERS OF ONE COMPANY’S SECURITIES IN THE AQUIRING COMPANY IN EXCHANGE FOR THE SURRENDER OF THEIR STOCK
  • 40.
    TYPES OF MERGERS Horizontalmerger  Horizontal merger is a business consolidation that occurs between firms who operate in the same space, often as competitors offering the same good or service. Vertical Merger  A vertical merger occurs when two or more firms, operating at different levels within an industry's supply chain, merge operations. Most often the logic behind the merger is to increase synergies created by merging firms that would be more efficient operating as one. Conglomerate merger  A merger between firms that are involved in totally unrelated business activities. There are two types of conglomerate mergers: pure and mixed. Pure conglomerate mergers involve firms with nothing in common, while mixed conglomerate mergers involve firms that are looking for product extensions or market extensions.
  • 41.
    EXAMPLES OF MERGERS YEARANNOUNCED ACQUIRER/RESULTANT COMPANY TARGET/MERGING COMPANIES ANNOUNCEDTOTAL VALUE($.bn) 2000 GLAXOSMITHKLI NE SMITHKLINEBEECHA M+ GLAXO WELLCOME 72.4 1998 ASTRAZENECA ASTRA+ZENECA 30.4 1996 NOVARTIS CIBA-GEIGY+SANDOZ 29 1999 PHARMACIA PHARMACIA&UPJOH N+ MONSANTO 25.2
  • 42.
    ACQUISITION OF PHARMACOMPANIES DEFINITION : When one company takes over another and clearly established itself as the new owner TYPES OF ACQUISITION  . Friendly Acquisition: Both the companies approve of the acquisition under friendly terms.  Reverse Acquisition: A private company takes over a public company.  Back flip Acquisition: The purchasing company becomes a subsidiary of the purchased company
  • 43.
    EXAMPLES OF AQUISITION AnnouncedDate Value in $ million Acquirer Acquired Firm Name Country Name Target nation 18 Feb 2014 28,407 Actavis plc United States Forest Laboratories Inc United States 22 April 2014 54,652. Valeant Pharmaceuticals International Inc Canada Allergan Inc United States 22 April 2014 23,050 Novartis AG, GlaxoSmithKline plc Switzerland, United Kingdom GlaxoSmithKline's oncology portfolio, R&D activities & AKT inhibitor rights / Novartis' vaccines business United Kingdom 6 May 2014 14,200 Bayer AG Germany Merck & Co Inc (Consumer Care Business) United States 20 June 2014 56,064.4 AbbVie Inc United States Shire plc United Kingdom 30 June 2013 10,248.2 Amgen Inc United States ONYX Pharmaceuticals Inc United States 19 May 2011 13,682 Takeda Pharmaceutical Co Ltd Japan Nycomed SCA SICAR Switzerland 21 July 2011 35,017.9 Express Scripts Inc United States Medco Health Solutions Inc United States 21 November 2011 11,017.1 Gilead Sciences Inc United States Pharmasset Inc United States 29 August 2010 24,476.7 Sanofi-Aventis SA France Genzyme Corp United States
  • 44.
    TAKE-OVERS DEFINITION When an acquiringcompany makes a bid for a target company. If the takeover goes through, the acquiring company becomes responsible for all of the target company’s operations, holdings and debt. When the target is a publicly traded company, the acquiring company will make an offer for all of the target’s outstanding shares.
  • 45.
    TYPES OF TAKE-OVERS TYPESOF TAKE-OVERS :  'Friendly Takeover' - the company bidding will approach the directors of the other company to discuss and agree an offer before proposing it to the shareholders of that company. The bidding company will also have an opportunity to look at the accounts of the business they want to buy - a process known as due diligence.  'Hostile Takeover' - the company bidding has their offer rejected or does not approach the board of the company they wish to buy before making an offer to shareholders. This also means they will not have access to private information about the company - increasing the risk of the takeover. Banks are usually more cautious about lending money for hostile takeovers.  'Reverse Takeover' - the final common type of takeover is the reverse takeover. This happens when a private (not traded on the stock market) company buys a publicly- traded company as a means of acquiring public status without having to list itself
  • 46.
    EXAMPLES OF TAKE-OVERS ZS PHARMA ACQUIRED ACTELION  PFIZER AQUIRED GSK’S MENINGOCOCCAL ACWY VACCINES  HORIZON PHARMA OF IRELAND ACQUIRED DEPOMED  MYLAN OF NETHERLAND ACQUIRED PERRIGO  CONCARDIA FROM CANADA ACQUIRED AMDIPHARM MERCURY  US BASED PURDUE PHARMA ACQUIRED TRKA PROGRAM OF VM PHARMA  CIPLA OF INDIA ACQUIRED INVAGEN AND EXELAN  PFIZER AQUIRED HOSPIRA  ALLERGAN TO ACQUIRE AQUESYS  LANNET ACQUIRED UCB’S KREMER URBAN GENERIC UNIT  AMICUS THERAUPETICS AQUIRED SCIODERM  SUCAMPO PHARMACEUTICALS AQUIRED R-TECH UENO
  • 47.
    SUCCESSFUL ENTREPRENEURS MR.BINISH CHUDGAR INTASPHARMACEUTICALS INCORPORATED IN 1976 HEAD OFFICE- AHMEDABAD ESTD.WEALTH - $2.79 BILLION FINISHED FORMULATIONS AND BIOLOGICS MR.PV.RAMPRASAD REDDY AUROBINDO PHARMA INCORPORATED IN 1986 HEAD OFFICE – HYDRABAD ESTD.WEALTH - $2.26 BILLION BULK AND FINISHED GOODS MR.MURALI.K.DIVI DIVI’S LABORATORIES INCORPORATED IN 1990 HEAD OFFICE – HYDERABAD ESTD.WEALTH - $1.93 BILLION APIs AND INTERMEDIATES
  • 48.
    SUCCESSFUL ENTERPRENEUR(Contd.) MR.SAMPRADA SINGH ALKEMLABORATORIES INCORPORATED IN 1973 HEAD OFFICE – MUMBAI ESTD.WEALTH - $1.69 BILLION PHARMACEUTICAL FINISHED FORMULATIONS DR.AZAD MOOPEN ASTER DM HEALTHCARE INCORPORATED IN 1987 HEAD OFFICE – KOCHI ESTD.WEALTH - $1.54 BILLION HOSPITALS AND DIAGNOSTIC CENTRES MR.DILIP SURANA MICRO LABS INCORPORATED IN 1973 HEAD OFFICE – CHENNAI ESTD.WEALTH- $1.49 BILLION BRANDED DRUGS AND APIs
  • 49.
    PRODUCTS OF SUNPHARMA THERAUPETIC AREAS PRODUCTS NEUROLOGY&PSYCHIATRY ACAMPROL ADCAPONE ALCOLIV AMIXIDE CARDIOLOGY AMLOBET AZTOR EZ AQUAZIDE 12.5 ANGIZEM 30 ORTHOPAEDIC BENZADAY 15 GASTEROENTEROLOGY ALCAINE-MPS 200ML 1 BTL UROLOGY TROFAME XR GYNOCOLOGY AFDURA RESPIRATORY AB PHYLLINE AQUAMET NASAL SPRA AB PHYLLINE SYRUP
  • 50.
    BRANDS OF SUNPHARMA THE MAJOR BRANDS OF SUN PHARMA ARE AS FOLLOWS
  • 51.
    GOVERNMENT POLICIES ONPHARMA INSUSTRY  PHARMACEUTICAL POLICY 2002  INDUSTRIAL LICENSING  FOREIGN INVESTMENT  FOREIGN TECHNOLOGY AGREEMENTS (FTA)  IMPORTS  PRICING  QUALITY ASPECTS  PHARMA EDUCATION AND TRAINING  NATIONAL PHARMACEUTICAL PRICING POLICY 2012  DRUG POLICY 1986
  • 52.
  • 53.
    IMPACT OF REGULATIONSON PHARMA INDUSTRY RECENT REGULATIONS OF THE GOVERNMENT THAT HAS IMPACT ON THE PHARMA INDUSTRY ARE LISTED BELOW  Move to establish an integrated regulatory system through the constitution of a National Drug Authority so that quality regulation and price control is performed by the same agency  Establishment of pharmacy vigilance centres at national, zonal and regional levels to monitor adverse drug reactions  Move to bring nearly 374 bulk drugs under price control and regulate trade margins  Capability strengthening to monitor clinical trials, including the setting up of the Clinical Trials Registry of India (CTRI)
  • 54.
    RECENT REGULATIONS &ITS IMPACT ON SUNPHARMA  National Program for Prevention and Control of Fluorosis (NPPCF)  National Tobacco Control Program (NTCP)  National Program for Health Care of the Elderly(NPHCE)  National Leprosy eradication program  Cancer Control Program  Cardio Vascular Diseases Eradication Program
  • 55.
    INFLATION DEFINITION: Inflation is thepercentage change in the value of the Wholesale Price Index (WPI) on a year-on year basis. It effectively measures the change in the prices of a basket of goods and services in a year. In India, inflation is calculated by taking the WPI as base. CAUSES OF INFLATION: DEMAND PULL INFLATION  Depreciation on rate change  Monetary stimulus to the economy  Fast growth in other countries COST PUSH INFLATION  Component cost  Rising labor cost  Higher indirect taxes  A fall in the exchange rate
  • 56.
    Inflation & ItsImpacts on Pharma Industry Shift towards a Networked business model. Increasing M&A and alliances Consolidation in the market INCREASE INVESTMENTS & MNC ACTIVITY Seen as the next volume driver, though costs of operation is high due to poor health infrastructure INCREASE REACH IN NON METRO MARKETS Though delayed from its April 2010 implementation date, GST will add significant efficiencies to economy and lead to an overhaul of supply chain GOODS & SERVICES TAX More numbers of patients will be coming in for treatment GROWING INSURANCE Shift towards biotech & speciality therapies, • increased investment in R&D and acute disease segment will sustain strong growth CHANGING DISEASE PROFILE Use of technology & IT for innovation in healthcare delivery • e.g. Mobile clinics HEALTH CARE INNOVATION
  • 57.
    DEFLATION DEFINITON: A general declinein prices, often caused by a reduction in the supply of money or credit. Deflation can be caused also by a decrease in government, personal or investment spending. The opposite of inflation, deflation has the side effect of increased unemployment since there is a lower level of demand in the economy, which can lead to an economic depression. Central banks attempt to stop severe deflation, along with severe inflation, in an attempt to keep the excessive drop in prices to a minimum. CAUSES OF DEFLATION:  Change in structure of capital market  Increased productivity  Decrease in currency supplies  Austerity measures
  • 58.
    Deflation & itsImpacts on Pharma Industry During the time of deflation, pharmaceutical industries face many problems. They are as follows:  Deflation will reduce the Foreign Direct Investments (FDI) because usually none of the investors will invest if there is a deflation in that country. Thus research & development on pharmaceutical sector will be reduced.  Deflation reduces the purchasing power of the people. At the time of inflation, income earned by the people will be reduced. Thus they cant afford to buy costly medicines. Thus the pharma companies have to reduce the price of the medicines. It will create loss to the company.  During deflation, the share prices of the pharmaceutical companies will be reduced. It will affect the global market scenario.  At the time of deflation, Government will reduce all the subsidies given to the pharmaceutical companies for research & development.
  • 59.
    RECESSION DEFINITION: A significant declinein the activity across the economy, lasting longer than a few months. It is visible in industrial production, employment, real income, and wholesale retail trade. The technical indicator of a recession is two consecutive quarters of negative economic growth as measured by a country’s GDP. EFFECTS OF RECESSION:  Uncertain exchange rate and a sudden increase in dollar value against indian rupees.  Delayed payment  Pharmaceutical products also doesn’t decrease.
  • 60.
    STOCK MARKET Stock marketis the place where the shares are being traded by the people and the companies. The main regulatory of the stock market is SECURITIES EXCHANGE BOARD OF INDIA (SEBI). SECURITIES EXCHANGE BOARD OF INDIA The following are some of the functions of SEBI. They are:  Protective function It Checks Price Rigging It Prohibits Insider trading SEBI prohibits fraudulent and Unfair Trade Practices  Development function Training to intermediaries promotional activities  Regulatory function framed rules and regulations restrictive on private placements conducts inquiries
  • 61.
    SUN PHARMA –STOCK MARKET PROFILE
  • 62.
    STOCK MARKET (ason 09/10/2015)
  • 63.
    REGULATORY OF PHARMAINDUSTRY OBJECTIVE OF THE REGULATORY: The present study describes a brief review of various regulatory bodies of major developed and developing countries around the world and the scope and challenges of such pharmaceutical regulatory organizations in delivery of safe and effective healthcare products MAJOR REGULATORY OF PHARMA INDUSTRY The major regulatory of pharma industry in India is CENTRAL DRUG STANDARD CONTROL ORGANISATION
  • 64.
    REGULATORY AUTHORITY Country Nameof Regulatory Authority USA Food and Drug Administration (FDA) UK Medicines and Healthcare Products Regulatory Agency (MHRA) Australia Therapeutic Goods Administration (TGA) India Central Drug Standard Control Organization (CDSCO) Canada Health Canada Europe European Medicines Agency (EMEA) Denmark Danish Medicines Agency Costa Rica Ministry of Health New Zealand Medsafe - Medicines and Medical Devices Safety Authority Sweden Medical Products Agency (MPA) Netherlands Medicines Evaluation Board Ireland Irish Medicines Board Italy Italian Pharmaceutical Agency Nigeria National Agency for Food and Drug Administration and Control (NAFDAC) Ukraine Ministry of Health Singapore Centre for Pharmaceutical Administration Health Sciences Authority Hong Kong Department of Health: Pharmaceutical Services Paraguay Ministry of Health Sweden Medical Products Agency (MPA) Thailand Ministry of Public Health China State Food and Drug Administration Germany Federal Institute for Drugs and Medical Devices Malaysia National Pharmaceutical Control Bureau,Ministry of Health Pakistan Drugs Control Organization, Ministry of Health South AfricaMedicines Control Council Sri Lanka SPC,Ministry of Health
  • 65.
    CONCLUSION INDIAN PHARMACEUTICAL INDUSTRYPLAYS A MAJOR ROLE IN INDUSTRIAL SECTOR IN DEVELOPING THE COUNTRY AS WELL AS MAKING THE WHOLE WORLD MARKET TO TURN AROUND TO SEE OUR COUNTRY. SUN PHARMACEUTICALS HAS A MAJOR PART IN DEVELOPMENT OF INDIAN PHARMACEUTICAL INDUSTRY BY PRODUCING DRUGS FOR MAJOR THERAUPETIC TREATMENTS WHICH IS SUPPORTED BY MORE THAN 150 COUNTRIES AND 5 CONTINENTS. IT IS EXPECTED THAT SUN PHARMA WILL BECOME TOP 1ST PHARMACEUTICAL COMPANY IN THE WORLD MARKET BY 2020.